Breaking AI & Tech News Analyzed

The Sequel Announcement The studio behind hit Michael Jackson biopic 'Michael' has revealed plans for a sequel despite the controversy that surrounded the original. Production Details Speaking in a quarterly earnings call, Lionsgate motion picture chair Adam Fogelson said that preparations for a projected sequel “continue to go exceptionally well”. Fogelson added that there is a lot of entertaining Michael Jackson story that was not touched upon in the first film. The Financial Impact The original film delivered record-breaking box office figures in both the US and UK, with its current revenue standing at $715.8m worldwide. Fogelson suggested that some of the previously shot footage could be utilised for the sequel, which would help lower the sequel’s production costs. Addressing Controversy The production of 'Michael' was dogged by issues surrounding allegations of child sex abuse against Jackson. It is not clear how or even if a sequel will deal with these allegations. However, Fogelson suggested that the sequel may not follow chronologically. The Future Outlook Lionsgate believes that they have 25 to 30% of a second movie already shot from the prior production activity. The studio is confident that the sequel will appeal once again to a global audience.

The Unseen Toll of War The conflict in Mali has had a profound impact on the mental health of its citizens. Beyond the physical destruction and loss of life, the war has left a lasting legacy of psychological trauma. Living with Trauma Survivors of the war often struggle with anxiety, depression, and post-traumatic stress disorder (PTSD). These conditions can make everyday tasks challenging and affect relationships with family and friends. The Need for Support Addressing the mental health needs of Malians affected by the war is essential for the country's recovery. This includes providing access to mental health services and supporting community-based initiatives. A Path Forward By acknowledging the mental trauma caused by the war, Mali can begin to heal and rebuild. It is crucial for the international community to provide support and resources to help the country address this critical issue.

The Childcare Crisis in BritainThe number of childminders in England has roughly halved over the past decade, with many citing rising costs, low pay and increasing paperwork as reasons for leaving the profession. Campaigners warn the decline is making it harder for families to find flexible and affordable childcare.Seeking Parent ExperiencesWe want to hear from parents and carers whose childminder has recently closed their business, stopped accepting certain age groups such those over three-year-olds or reduced the number of children they look after.Impact on FamiliesHow did it affect your family? Did you struggle to find alternative childcare? Have you been forced to move your child into a nursery setting despite feeling they were better suited to a smaller, home-from-home environment?Share Your StoryThe Guardian is collecting experiences from parents affected by the decline in childminding services. If you're 18 or over, you can share your story anonymously if you wish. Your responses are secure as the form is encrypted and only The Guardian has access to your contributions.Call for ActionAs the childcare landscape continues to change, it's crucial to understand how these changes are affecting families across the UK. By sharing your experiences, you can help highlight the challenges and potential solutions in the childcare sector.

Retatrutide Delivers Up to 28% Body‑Weight Reduction in Phase 3 StudyA new weight‑loss drug has helped participants in a sizable trial lose much more weight than other obesity drugs already on the market – up to an average of 28% of their body weight, Eli Lilly announced on Thursday. Phase 3 Trial Design and Dosing RegimenThe Indiana‑based company randomized 2,339 adults with obesity or overweight and at least one weight‑related comorbidity (no diabetes) to receive Retatrutide at 4 mg, 9 mg, 12 mg, or placebo for 80 weeks. The drug is a once‑weekly triple hormone receptor agonist targeting GLP‑1, GIP, and glucagon. Quantitative Outcomes and Safety ProfileAverage weight loss: 70.3 lb (28.3%) at the 12 mg dose.Average loss at 9 mg: 64.4 lb (25.9%).Average loss at 4 mg: 47.2 lb (19.0%).45.3% of 12 mg participants lost ≥30% of body weight.65.3% reduced BMI below 30; 37.5% of those starting with BMI ≥ 40 achieved this.Side‑effects increased with dose: nausea (28.6%‑42.4%), diarrhea (25.2%‑34.1%), vomiting (up to 25%).For comparison, Zepbound yields 15‑20% loss over 72 weeks and Wegovy 14‑19% over 64‑72 weeks. Implications for the Obesity‑Drug LandscapeThe magnitude of loss positions Retatrutide as the most effective pharmacologic option to date, potentially shifting prescriber preference away from existing GLP‑1 monotherapies. Its triple‑agonist mechanism adds glucagon, a hormone absent from current products, which may enhance metabolic control and appetite suppression. Future Outlook: Approval Path and Market PotentialAnalysts expect regulatory submissions within the next year, with a likely U.S. FDA review in 2027. If approved, Retatrutide could capture a sizable share of the rapidly expanding obesity‑treatment market, prompting competitors to explore multi‑agonist formulations.

The Lead: Japan's World Cup AmbitionsJapan have been late bloomers in terms of World Cups, only reaching the tournament for the first time in 1998 – but since then they have been at every edition. While they have never gotten past the last 16, their current crop of players is surely the most talented in the national side's history.Statement Victory: Japan's Rising International StatusJapan were the first team – outside the hosts – to qualify for the 2026 World Cup. The Samurai Blue have beaten Germany, Brazil, England and Spain since 2022. Their recent 1-0 win at Wembley against England in March, courtesy of a Kaoru Mitoma goal, sent a clear statement about their growing international prowess.Key Players: Mitoma's Absence and Kubo's PromiseJapan's preparations were dealt a blow with star player Kaoru Mitoma missing the tournament due to a hamstring injury. However, Japanese right-winger Takefusa Kubo has promised to fill the void. The 24-year-old has had a fantastic season at Real Sociedad, where he has tormented the best defences of La Liga and helped his side lift the Copa del Rey.Team Structure: Strong Backbone and Tactical FlexibilityWhile coach Hajime Moriyasu's side relish unleashing their attacking talent when possible, they can be pragmatic when needed – playing a low block and keeping things tight – and have a strong backbone. Former Arsenal defender Takehiro Tomiyasu has made the 26-man squad, despite not playing for the Samurai Blue for almost two years due to injuries. In midfield, Wataru Endo offers versatility alongside his leadership and defensive screening, while Daichi Kamada of Crystal Palace offers creativity in the middle of the park.Group Analysis: Path Through Group FJapan will surely qualify from Group F, with their opener against the Netherlands likely to be the stiffest test but also an opportunity to send a statement about their intentions. Tunisia and Sweden will probably not have enough quality to contain the Japanese, but the Blue Samurai certainly will not want to be getting complacent.Future Outlook: Breaking the Last 16 BarrierJapan may well break their last 16 hex – but the last eight will likely be as far as it goes for a side whose limitations will probably catch up with them. The psychological weight of so many last 16 exits is something the Blue Samurai will have to find a way to shrug off if they are to achieve greater success in 2026.Squad Breakdown: Key Names to KnowGoalkeepers: Zion Suzuki, Keisuke Osako, Tomoki Hayakawa.Defenders: Yuto Nagatomo, Shogo Taniguchi, Ko Itakura, Tsuyoshi Watanabe, Takehiro Tomiyasu, Hiroki Ito, Ayumu Seko, Yukinari Sugawara, Junnosuke Suzuki.Midfielders: Wataru Endo, Junya Ito, Daichi Kamada, Ritsu Doan, Ao Tanaka, Kaishu Sano, Takefusa Kubo, Yuito Suzuki.Forwards: Daizen Maeda, Koki Ogawa, Ayase Ueda, Keito Nakamura, Kento Shiogai, Keisuke Goto.

Tragic Loss of a Racing IconThe NASCAR community is in shock after the death of Kyle Busch, a two‑time Cup Series champion and record‑holding winner across NASCAR’s three national series. He passed away at 41 following a brief hospitalization for a “severe illness.”Details of the Illness and HospitalisationBusch was testing in the Chevrolet racing simulator in Concord on Wednesday when he became unresponsive. He was rushed to a Charlotte hospital and died the following day. The family, Richard Childress Racing, and NASCAR released a joint statement confirming his death but did not disclose a cause.Wednesday: Unresponsive during simulator test; transported to hospital.Thursday: Family announces death; no cause released.Three days before scheduled start in the Coca‑Cola 600 at Charlotte Motor Speedway.Career Statistics Highlighting Busch’s RecordBusch’s achievements set him apart in modern motorsport:Combined wins: 234 across Cup, Xfinity (O’Reilly Auto Parts) and Trucks series.Cup victories: 63 wins.Xfinity wins: 102 wins (record).Truck Series wins: 69 wins (record).Championships: Cup Series titles in 2015 and 2019 with Joe Gibbs Racing.Rookie of the Year: 2005.Repercussions for NASCAR and the Racing CommunityThe loss reverberates through teams, drivers, and fans. Statements from NASCAR, teammates Denny Hamlin and Brad Keselowski expressed “heartbreak” and “absolute shock.” Busch’s role as an owner in the Truck Series and his outspoken personality helped build the devoted “Rowdy Nation” fan base.His career also illustrates the sport’s competitive dynamics, from early dismissal by Hendrick Motorsports to a dominant stint with Joe Gibbs Racing, and later challenges with Richard Childress Racing.Looking Ahead: Legacy and Future of the SportWhile the immediate future of Busch’s teams remains uncertain, his impact is likely to be cemented with Hall of Fame consideration and continued reverence from fans and fellow drivers. The sport may also see increased focus on driver health monitoring, given the sudden nature of his decline.

Executive Summary of the Podcast EpisodeThe Guardian’s latest podcast follows hunters who argue that shooting big game can help preserve Africa’s wildlife, sparking a nuanced discussion on conservation strategies.Episode Focus and How to Access ItListen or read: Read the text version hereSupport the Guardian: theguardian.com/longreadpodRelated Publication Highlighted in the EpisodeThe episode references Adapted from The Savage Landscape: How We Made the Wilderness by Cal Flyn, published by William Collins on 7 May. The book can be ordered via guardianbookshop.com.Visual Context ProvidedPhotograph: ReutersWhy This Conversation MattersThe podcast adds to ongoing debates about the role of regulated hunting in wildlife management, offering perspectives from those directly involved in the practice.Looking AheadFuture episodes and related reporting are expected to continue exploring the complex balance between hunting, conservation funding, and ecosystem health across Africa.

The Man Behind the Enhanced Games Christian Angermayer, a German billionaire with a reputation for being audacious, is the mastermind behind the Enhanced Games, an event that has left the sporting world in shock. Dubbed the 'Steroid Olympics' by critics, the competition allows athletes to use performance-enhancing drugs, a move that has been met with fierce criticism from anti-doping authorities. Angermayer's Vision for Sports Angermayer's vision for sports is one where athletes are free to use medically approved drugs, with close medical supervision, to enhance their performance. He argues that this approach could revolutionize the way we think about sports and health, and that it could even help to prevent injuries and illnesses. The Data Behind the Enhanced Games According to a study by the Enhanced Games, 91% of athletes competing in the event are using testosterone, 79% are using human growth hormone, and 41% are using EPO. These numbers are likely to raise concerns about the safety and fairness of the event. The Impact on the Sporting World The Enhanced Games have sparked a heated debate about the use of performance-enhancing drugs in sports. While some argue that it is a recipe for disaster, others see it as an opportunity to challenge traditional notions of athletic achievement. Angermayer believes that his event will be watched by millions of people and that it will help to popularize the use of performance-enhancing drugs for non-athletic purposes. The Future of the Enhanced Games As the Enhanced Games prepare to take place, Angermayer is confident that his event will be a success. Despite criticism from anti-doping authorities and others, he believes that he is on the right side of history. Whether the event will live up to its promise remains to be seen, but one thing is certain: the Enhanced Games are set to shake up the world of sports like never before.

The Grand Slam Pay Dispute Wimbledon will offer to create a new player council in a meeting with leading player representatives scheduled for Roland Garros next week, with Tim Henman having intervened in the ongoing row over grand slam prize money. Henman's Intervention The former British No 1 and All England Club Board member held talks with several top players, including representatives of the WTA Players’ Council at the Italian Open in Rome earlier this month. A formal meeting between Wimbledon officials and player agents at the French Open will follow. The Data Behind the Dispute The French Open's income last year increased by 14% to €395m. The players' representatives have requested a greater percentage of revenue for players and contributions to welfare initiatives, such as pension funds. Wimbledon's prize fund for this year will be revealed at a press conference on 11 June. The Impact on the Tennis Community The dispute has led to player protests and potential boycotts, with some players agreeing to reduce their media activities at the French Open in a coordinated protest. The players will only participate in pre-tournament press conferences with written media and conduct one interview with a host broadcaster. The Future of Grand Slam Prize Money It is unclear if Henman's intervention has helped bring the players to the negotiating table, but given his status in the sport, the 51-year-old may have helped to smooth relations. Wimbledon, the French Open and US Open have been open to meeting the top players’ representatives to discuss concerns over prize money, welfare and representation since December.